DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for autoimmune thrombocytopenic purpura — screening already-approved drugs against its 41-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAutoimmune thrombocytopenic purpura maps to a 41-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for autoimmune thrombocytopenic purpura is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
macrophage migration inhibitory factor (MIF) — MIF is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ipadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9JIT · 1.08 Å · ligand ISOPROPYL ALCOHOL (IPA). Experimental structure, not a prediction.
What the evidence adds up to
A 2008 review of refractory immune thrombocytopenic purpura in children notes that the condition is infrequent but carries substantial morbidity and mortality. Management is controversial because treatment options have not been directly compared and definitions of refractory disease vary. The review states that recent studies have identified a dominant proinflammatory state, inadequate thrombopoiesis, and disturbances in B and T lymphocytes as part of the pathogenesis. New agents targeting these mechanisms, such as anti-CD20 monoclonal antibody and thrombopoietic agents, showed promising results in clinical trials conducted primarily in adults. The review concludes that management often requires multiple agents that may provide only short-term benefit, and that lack of clear guidance on medication use, side effects, and inability to target a specific patient’s disease lead to frustration.
A 1980 report on two adults with idiopathic thrombocytopenic purpura refractory to conventional therapy describes treatment with plasma exchange. In both cases the therapy was unsuccessful in controlling their disease. The authors suggest that in refractory adult-onset ITP, plasma exchange may not be an effective mode of therapy.
A 2006 article characterises ITP as an inflammatory and autoimmune disorder with transient or long-term disturbed immune response. It states that since 1980 ITP has become a model for targeted therapeutic immunomodulation, but the mechanisms of action remain unclear. The article calls for more clearly defined patient subgroups for targeted therapy and for further exploration of the complex immune disturbances in this disorder.
A 2022 article discusses the effectiveness of treatment with modern drugs and new methods for idiopathic thrombocytopenic purpura, but its abstract provides no specific data on response rates, survival, or sample sizes. What is still missing are direct comparative trials of existing therapies, validated definitions of refractory disease that allow consistent patient stratification, and funding for studies that can identify which immunological subtype a given patient belongs to before selecting a treatment.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Pediatrics · 2008 · 30 citations
Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura
AbstractPURPOSE OF REVIEW: Refractory immune thrombocytopenic purpura is infrequent in children, but carries substantial morbidity and even mortality. Management of these children is controversial despite the availability of several treatment options as these strategies have not been directly compared and there are many definitions for refractory immune thrombocytopenic purpura. This review will provide an update on the pathogenesis, diagnosis and treatment options for children with severe, acute and chronic refractory immune thrombocytopenic purpura. RECENT FINDINGS: Recent studies have demonstrated a number of immunologic alterations (dominant proinflammatory state, inadequate thrombopoiesis, and various B and T lymphocyte disturbances) in the pathogenesis of chronic immune thrombocytopenic purpura. New agents that target certain of these mechanisms (e.g. anti-CD20 monoclonal antibody, thrombopoietic agents) have shown promising results in recent clinical trials, primarily but not solely in adults. SUMMARY: Management of refractory immune thrombocytopenic purpura often requires multiple agents that may provide only short-term benefit. Lack of clear views about the use of these medications, their unwanted side effects and an inability to specifically target a particular patient's disease all lead to frustration among patients, family and the physicians. Better understanding of pathogenesis with the availability of newer therapies with different mechanisms of effect should, however, allow improved management of these patients.
Archives of Internal Medicine · 1980 · 14 citations
Plasma Exchange in Idiopathic Thrombocytopenic Purpura
AbstractTwo cases of adult-onset idiopathic thrombocytopenic purpura (ITP), refractory to conventional therapy, were treated. Because of recent successful reports of plasma exchange in ITP, this technique was performed on each patient. In both cases, the therapy was unsuccessful in controlling their disease, suggesting that in refractory adult-onset ITP, plasma exchange may not be an effective mode of therapy.
Development and research in idiopathic thrombocytopenic purpura: An inflammatory and autoimmune disorder
AbstractBleeding and isolated thrombocytopenia in idiopathic thrombocytopenic purpura (ITP) are phenomena of a transient or long-term disturbed immune response. Since 1980, ITP has become a model for targeted therapeutic immunomodulation with still unclear mechanisms of action. The systematic analysis of ITP aims to determine more clearly defined patient subgroups for targeted therapy and to explore the complex immune disturbances in this autoimmune disorder.
International Journal for Research in Applied Science and Engineering Technology · 2022 · 0 citations · open access
The Effectiveness of The Treatment of Idiopathic Thrombocytopenic Purpura with Modern Drugs
AbstractAbstract: This article discusses the effectiveness of treatment of idiopathic thrombocytopenic purpura with modern drugs and its new methods. Primary immune thrombocytopenia, commonly referred to as idiopathic thrombocytopenic purpura (ITP), is an acquired autoimmune disease characterized by isolated thrombocytopenia. Keywords: treatment, idiopathic thrombocytopenic purpura, modern drugs, new methods, clinical fetures, disease
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
